Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Genmab pays $8B to buy Merus and phase 3 bispecific
Genmab is continuing to build its pipeline of wholly owned cancer assets, this time paying $8 billion for Merus and its bispecific antibody.
James Waldron
Sep 29, 2025 5:38am
Roche's obesity ambition not reliant on one megablockbuster
Sep 23, 2025 7:45am
Glooko buys Monarch’s EndoTool to enter in-patient diabetes care
Sep 23, 2025 7:30am
Pfizer inks $4.9B Metsera buyout to beef up obesity pipeline
Sep 22, 2025 7:47am
GE HealthCare considering stake sale in China division: report
Sep 18, 2025 2:30pm
Biogen inks $85M Alcyone buyout to acquire drug delivery tech
Sep 18, 2025 10:30am
